Vilon
Community reportsTwo amino acids sold for anti-aging, with decades of promotion but no registered clinical trial under its own name.
What it is
Vilon is a tiny dipeptide made of just two amino acids, lysine and glutamic acid. It comes from a Russian program that studied short peptides extracted from tissues. It is marketed to slow aging, support immunity, and hold back cancer, and its anti-aging story has been running for three decades.
How it works
The pitch rests on cell-culture numbers: the compound is reported to raise a longevity-linked gene and its protein, boost collagen in aged skin cells, and lower inflammatory signals in blood cells. Those are real figures from real journals, but every one was measured in a dish, not in a body.
What people report
- ✦Cheap to make: just two amino acids joined together
- ✦The cell-culture figures quoted by vendors are genuine published numbers
- ✦Carries history from a larger, officially registered short-peptide program
- ✦Long-standing presence in the anti-aging market
Typical use
None exists. There is no registered trial for vilon under any registry reviewed.
Dosing reference
No reference human dosing. Verify against primary literature before any research use.
Reference only — not a recommendation. Verify via primary sources.
Watch for
The longevity claim was tested head-to-head and the benefit went to a different molecule. One of the best studies in the set, run by the inventors themselves, found vilon was associated with increased mammary cancer in mice. The human immune claim has never been tested.
Educational content — not medical advice.